Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumor
Company Creates “Younger T Cells” for Fighting Cancer Using its NR2F6 Technology
Excerpt from the Press Release:
SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion”.
CAR-T cells are very effective at treating certain lymphomas and leukemias with an overall cure rate of over 50%4. However, solid tumors remain resistant to CAR-T therapies for many reasons. One reason is “T cell exhaustion”, a term that means T cells that are initially recruited to the tumor to kill it end up losing their effectiveness .
The technology covered by this patent application introduces a novel type of T cell which is resistant to the immune suppressive effects of the tumor and prevents this exhaustion. The disclosed technology induces an intracellular program in T cells to endow them with certain features of “younger” cells, thus allowing for enhanced activity against conventional solid tumors such as lung, skin, breast and brain cancers. This includes inhibiting NR2F6, a T cell checkpoint which the Company has been focusing on.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?